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Abstract Phosphatidylinositide-3-OH-kinase (PI 3-kinase) is
an upstream activator of p42/p44 mitogen-activated protein
kinase (MAPK), but the role of PI 3-kinase-dependent MAPK
remains obscure. Here we demonstrate that in a variety of
different cell types, PI 3-kinase inhibition results in an inhibition
of MAPK in unstimulated cells but does not interfere with
growth factor-, or TPA-induced MAPK activity. Furthermore,
inhibition of either PI 3-kinase or MEK/MAPK results in cell
death in serum-starved cells. We concluded that basal, but not
induced MAPK activity is mediated by PI 3-kinase and that this
PI 3-kinase-mediated MEK/MAPK activity is essential for cell
survival in quiescent cells.
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1. Introduction
The lipid and protein kinase phosphatidylinositide-3-OH-
kinase (PI 3-kinase) synthesises phosphatidylinositol-3-phos-
phate, phosphatidylinositol-3,4-diphosphate, and phosphati-
dylinositol-3,4,5-triphosphate from phosphatidylinositol,
phosphatidylinositol-4-phosphate, and phosphatidylinositol-
4,5-diphosphate respectively. Several PI 3-kinase isoforms,
such as PI 3-kinase K, L and Q, have been described, which
mostly consist of a catalytic and a regulatory subunit and,
although catalysing similar biochemical reactions, seem to
mediate speci¢c biochemical functions (for a review see Van-
haesebroeck et al. [1]). The availability of the pharmacological
PI 3-kinase inhibitors wortmannin [2] and LY294002 [3] as
well as the availability of catalytically inactive dominant neg-
ative PI 3-kinase constructs has now led to discovery of a
wide variety of biological processes involving PI 3-kinase, in-
cluding inhibition of apoptosis, receptor-stimulated signalling,
and the regulation of membrane tra⁄c. In general, it is as-
sumed that these e¡ects are brought about by the binding of
phosphatidylinositol-4,5-biphosphate and phosphatidylinosi-
tol-3,4,5-triphosphate to the pleckstrin homology domains of
downstream e¡ectors like the phosphatidylinositol-4,5-biphos-
phate/phosphatidylinositol-3,4,5-triphosphate-dependent ki-
nase 1, which in turn is an upstream activator of protein
kinase B (PKB, also known as c-Akt) [4]. Other important
cellular targets of PI 3-kinase include BAD [5,6], p21Rac
[7,8], S6 kinase (e.g. [4]), focal adhesion signalling [9,10],
and the respiratory burst in granulocytes [11].
During the last years, several reports have described the
e¡ects of PI 3-kinase activity on activation of the mitogen-
activated protein kinase (MAPK) pathway. Several investiga-
tors have found MAPK activation by insulin to be sensitive to
the PI 3-kinase inhibitor wortmannin [12,13]. This phenomen-
on is, however, hypothesised to be cell type and stimulus
speci¢c [14]. The type of PI 3-kinase involved is subject to
discussion as well ; some reports claim PI 3-kinase K to be
the activator of the MAPK pathway [15,16], whereas other
publications suggest that PI 3-kinase Q [17] might exert this
e¡ect. Very recently, Bondeva et al. [18] demonstrated an in-
crease in phosphorylated p42/p44 MAPK levels in serum-
starved COS7 cells transfected with di¡erent PI 3-kinase Q
hybrids. This e¡ect was not dependent on lipid kinase activity
or membrane localisation of PI 3-kinase Q, indicating that the
physical interaction between PI 3-kinase and Ras [19] is not
important for this e¡ect. The importance, however, of PI 3-
kinase for MAPK enzymatic activity remains relatively poor
de¢ned.
Cell survival is critically dependent on several intracellular
signalling routes. As stated above, PI 3-kinase has been shown
to play a pivotal role in cell survival by the subsequent acti-
vation of the protein kinase Akt/PKB and BAD. Both PKB
and BAD, the last being a member of the Bcl-2 family, have
important anti-apoptotic actions. Interestingly, BAD is not
only a substrate for PKB but is also phosphorylated by the
MAPK kinase MEK [20], linking the classical Ras-MAPK
pathway to cell survival. This notion is supported by several
studies, which show a role for this signalling module in cell
survival [21,22]. The interplay of PI 3-kinase- and MAPK-
associated signal transduction in cell survival remains unclear.
Hence, we set out to investigate the role of basal PI 3-kinase
activity in cellular MAPK activation. Furthermore we have
investigated the in£uence of pharmacological inhibition of PI
3-kinase and MAPK on cell survival. Here we show that the
PI 3-kinase inhibitors wortmannin and LY294002 are able to
decrease constitutive MAPK activity but do not signi¢cantly
e¡ect epidermal growth factor (EGF)-, 12-0-tetradecanoyl-
phorbol-13-acetate (TPA)-, or insulin-induced MAPK activa-
tion in A14 ¢broblasts, murine macrophages, COS cells and
Chinese hamster ovary (CHO) cells. In addition, in quiescent
cells PI 3-kinase and activity of the MAPK pathway are es-
sential for cell survival, suggesting that either MEK or MAPK
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is an important anti-apoptotic e¡ector of PI 3-kinase under
these conditions.
2. Materials and methods
2.1. Cell culture
A14 ¢broblasts and COS cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM), supplemented with 10% foetal calf serum
(FCS) in a humidi¢ed environment at 37‡C and 5% CO2. A murine
spleen macrophage cell line (clone 4-4, [23]) and Chinese hamster
ovary (CHO) cells were cultured in RPMI-1640 medium, with 10%
FCS under the same conditions as described above. Cells were pas-
saged every 2 days. Preincubations were done with ¢nal concentra-
tions of 100 nM wortmannin, 2 WM forskolin, 20 WM PD098059 and
10 WM LY294002. All inhibitors were solved in DMSO and added to
the media in a 1:1000 dilution. DMSO controls were without e¡ect.
2.2. Kinase phosphorylation assays
Cells were grown on 8-cm diameter dishes and after extensive wash-
ing with PBS to remove all serum, the cells were serum starved for
24 h. Subsequently, the cells were preincubated for 10 min with the
above mentioned inhibitors. Cells were stimulated for 15 min with
1 Wg/ml insulin, 1 Wg/ml TPA, 10 ng/ml EGF or 10% FCS as appro-
priate in the same medium. After stimulation, the cells were washed
with ice cold PBS and lysed by scraping in 150 Wl protein sample
bu¡er (125 mM Tris/HCl, pH 6.8; 4% SDS; 2% L-mercaptoethanol;
20% glycerol, 1 mg bromophenol blue). 50 Wl of the lysates, corre-
sponding with approximately 2U106 cells were loaded on a 10% SDS-
PAGE gel and after protein separation the proteins were blotted onto
PVDF membrane. To check for equal loading of protein in each lane,
Coomassie Brilliant Blue staining of the PVDF membrane was per-
formed. Subsequently, membranes were blocked in 2% bovine serum
albumin in PBS, supplemented with 0.1% Tween-20 and washed three
times for 10 min with 0.2% BSA in PBS supplemented with 0.1%
Tween-20. Raf, MEK, MAPK and PKB activation were determined
by incubating the immunoblots with antibodies against phosphory-
lated Raf (Ser259), MEK (Ser217=221), MAPK (Thr202/Tyr204) and
PKB (Ser473), used in a 1:1000 dilution for 1 h. The blots were washed
three times with wash bu¡er for 10 min and subsequently secondary
antibody incubations were performed for 1 h with horseradish perox-
idase-conjugated goat anti-rabbit immunoglobulins (GAR-PO) in a
1:2000 dilution. After enhanced chemoluminescence using Lumilight
substrate, antibody binding was visualised using a Lumi-imager.
2.3. Survival assay
A14 cells were plated in 24-well plates and cultured in serum-free
DMEM or serum-containing DMEM. Before using serum-free
DMEM, the cells were washed twice with 10 ml of phosphate-bu¡ered
saline (PBS) prior to adding serum-free DMEM, in order to remove
all serum. The cells were left untreated or treated with either 20 WM
PD98059 or 10 WM LY294002. Cell survival was measured for 5 sub-
sequent days according to the method described by Rubinstein et al.,
1990 [24]. Shortly, cells were incubated with 0.5 mg/ml 3-[4,5-dime-
thylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), which was
added directly into the media in a 10U concentrated solution, for
30P at 37‡C. Subsequently, the cells were lysed in isopropanol/0.04 N
HCl. The solution was transferred to a 96-well plate and the OD590=650
was determined. Survival was determined as a percentage of untreated
cells.
The stability of PD95059 in serum-containing medium was deter-
mined by adding the compound to the cells in a ¢nal concentration of
20 WM. Cells were lysed after 2, 4, 8, 24 and 48 h. Samples were
compensated for the total amount of protein, and loaded on a 10%
SDS-PAGE, after which Western blotting was performed. Detection
of MAPK phosphorylation was performed as described above.
2.4. Materials
DMEM and FCS were from Gibco and RPMI-1640 was from Bio-
Whittaker. PD98059, forskolin, EGF, insulin, TPA, wortmannin,
BSA and MTT were purchased from Sigma. LY294002 was from
Alexis/Kordia. All phosphospeci¢c antibodies were obtained from
New England Biolabs, secondary antibody (GAR-PO) was obtained
from DAKO. Lumilight substrate and the Lumi-imager were from
Boehringer Mannheim.
3. Results
3.1. The PI 3-kinase inhibitor wortmannin inhibits basal, but
not stimulated MAPK activation in ¢broblasts
Both recent ¢ndings that transfection of cells with PI 3-
kinase Q constructs resulted in MAPK activation [18] and
the observation that wortmannin can inhibit MAPK activa-
tion in stimulated cells [12,13] raises problems as to the im-
portance of endogenous PI 3-kinase in MAPK stimulation.
Therefore, we decided to investigate the e¡ect of endogenous
PI 3-kinase on both stimulated and constitutive MAPK activ-
ity. To this end serum-starved A14 cells were pre-treated with
the speci¢c PI 3-kinase inhibitor wortmannin, and cells were
subsequently stimulated with 100 ng/ml insulin or left unsti-
mulated. After immunoblotting, the phosphorylation states of
both MAPK and PKB were assayed by screening with phos-
phospeci¢c antibodies. The assumption was made that in-
creased immunoreactivity corresponded with activation of
the signalling components involved [4,25]. As depicted in
Fig. 1, untreated cells displayed constitutive phosphorylation
of MAPK. A 10-min incubation of the cells with wortmannin,
however, inhibited this constitutive MAPK phosphorylation.
Furthermore, the wortmannin treatment completely abolished
phospho-PKB immunoreactivity, demonstrating that inhibi-
tion of MAPK by wortmannin correlates with a concomitant
inhibition of well-established downstream targets of PI 3-ki-
nase. This was con¢rmed in [3H]-phosphoinositide measure-
ments in which the in£uence of wortmannin on PI 3-kinase
activity was assessed directly (not shown). Stimulation of cells
with insulin, however, did not result in a wortmannin-sensitive
MAPK activation. Apparently, PI 3-kinase is required for
basal MAPK activation in this cell type, but not for insulin-
induced MAPK activation.
3.2. c-Raf and MEK are involved in the wortmannin-sensitive
basal activation of MAPK
To obtain further information on this PI 3-kinase-depend-
ent MAPK stimulation, A14 cells were treated with forskolin
and PD98059, inhibitors of c-Raf [26] and MEK [27], respec-
tively. Both treatments completely abolished constitutive
MAPK phosphorylation, demonstrating that PI 3-kinase-de-
pendent MAPK stimulation is mediated via the Raf/MEK
pathway and does not involve an alternative signalling mech-
anism (Fig. 2A). Surprisingly, inhibition of MAPK by forsko-
lin or PD098059 resulted in increased PKB phosphorylation
Fig. 1. Wortmannin inhibits basal, but not insulin-induced MAPK
phosphorylation. After serum starvation, A14 cells were incubated
with insulin for 15 min or left untreated, either in the presence or
the absence of wortmannin (Wm). After cell lysis, the proteins were
separated on a 10% SDS-PAGE and subsequently immunoblotted
with polyclonal phosphospeci¢c p42/p44 or phosphospeci¢c PKB
antibodies.
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(Fig. 2A). At present we have no data to explain the molec-
ular basis of this e¡ect but it is tempting to suggest that in
unstimulated cells MAPK exerts negative feedback on PI 3-
kinase activity, providing further support for an involvement
of both c-Raf and MEK, since treatment of cells with wort-
mannin resulted in decreased c-Raf and MEK phosphoryla-
tion (Fig. 2B). In contrast to insulin-dependent MAPK stim-
ulation, serum-induced MAPK and MEK activation was
partly sensitive to wortmannin treatment (Fig. 2C), suggesting
a role for PI 3-kinase in maintaining constitutive MAPK ac-
tivity not only in quiescent cells, but in serum-treated cells as
well.
3.3. Wortmannin and LY294002 inhibit basal MAPK
activation in A14 cells, murine macrophages, COS cells
and CHO cells
Apart from wortmannin, LY294002 is a speci¢c inhibitor of
PI 3-kinase activity. As expected, both inhibitors impaired
constitutive MAPK activity in A14 ¢broblasts (Fig. 3A).
A14 cells overexpress the human insulin receptor, a strong
activator of PI 3-kinase, and therefore regulation of this ki-
nase in this cell type may not be representative. Therefore, we
decided to investigate the role of PI 3-kinase in a panel of
di¡erent cell types. As demonstrated in Fig. 3, in addition to
A14 ¢broblasts, PI 3-kinase inhibitors induce a decrease in
basal MAPK phosphorylation in murine macrophages, COS
cells and CHO cells as well, further con¢rming a role for PI 3-
kinase in constitutive MAPK activation. Neither wortmannin
nor LY294002, however, inhibited MAPK activation after
stimulation with EGF or TPA in ¢broblasts, macrophages
and COS cells. CHO cells, in our hands, exhibited very high
levels of basal MAPK phosphorylation, comparable to those
observed after stimulation with various agents. However,
whereas the basal levels of phosphorylated MAPK were again
sensitive to both wortmannin and LY294002, insulin- and
TPA-induced increases in phosphorylated MAPK were com-
pletely or partially insensitive to either wortmannin or
LY294002 treatment. These data demonstrate that PI 3-kinase
inhibitors do not abrogate signalling towards MAPK per se,
Fig. 3. E¡ects of LY94002 and wortmannin on constitutive and
stimulated MAPK activation. After serum starvation, A14 cells (A),
murine macrophages (B) and COS cells (C) were treated mock (un-
stimulated), with EGF, or with TPA, either in the presence or ab-
sence of wortmannin (Wm) and LY294002 (LY). CHO cells (panel
D) were treated mock (unstimulated), with insulin or TPA, also in
the presence or absence of wortmannin and LY294002. Subse-
quently, all cells were lysed, separated on 10% SDS-PAGE and im-
munoblotted with polyclonal phosphospeci¢c p42/p44 antibodies.
Fig. 2. MAPK activation in quiescent cells is mediated via c-Raf
and MEK in a wortmannin-sensitive manner. A: After serum star-
vation and if appropriate, incubation with wortmannin (Wm), for-
skolin (forsk), PD098059 (PD), A14 cells were lysed, the proteins
were separated on a 10% SDS-PAGE and immunoblotted with pol-
yclonal phosphospeci¢c p42/p44 (MAPK) or phosphospeci¢c PKB
antibodies. B: Cells were either or not treated with wortmannin for
15 min and lysates from these cells were used for immunoblotting
with phosphospeci¢c Raf and MEK antibodies. C: Serum-starved
A14 ¢broblasts either or not pre-incubated with wortmannin (Wm),
were stimulated with 10% foetal calf serum (FCS) or left untreated.
After cell lysis, proteins were separated on a 10% SDS-PAGE and
immunoblotted with polyclonal phosphospeci¢c antibodies.
FEBS 23129 27-12-99
H.H. Versteeg et al./FEBS Letters 465 (2000) 69^73 71
but that PI 3-kinase may therefore be speci¢cally involved in
the constitutive activation of MAPK.
3.4. Inhibition of basal MAPK and PI 3-kinase but not induced
MAPK levels lead to cell death
The role of PI 3-kinase and its downstream targets in cell
survival is well established. However, the action of the classi-
cal Ras-MAPK pathway in cell survival is much less de¢ned.
Therefore we decided to subject both serum-starved and se-
rum-treated A14 cells to either the PI 3-kinase inhibitor
LY294002 or to PD98059 by adding them to the cells prior
to the experiment. In serum-starved cells, either of the two
inhibitors proved su⁄cient to reduce cell survival, when com-
pared to untreated cells (Fig. 4A). Serum-treated, proliferating
cells also showed an LY294002-dependent increased cell
death. However, treatment of serum-treated cells with
PD98059 had little e¡ect (Fig. 4B), and thus PD98059 is not
toxic for cells per se. Addition of fresh PD98059 to the me-
dium every day gave similar results (not shown), and when
tested in serum-containing medium, PD98059 was able to in-
hibit MEK-dependent MAPK phosphorylation for at least
2 days (Fig. 4C), ruling out any e¡ects caused by breakdown
of PD98059 in the medium. Apparently, in quiescent cells
both activation of the MAPK pathway and PI 3-kinase activ-
ity are required for cell survival, whereas in the presence of
serum, activation of the MAPK pathway is not essential.
4. Discussion
Many intracellular processes responsible for cell survival
have been unravelled in recent years. PI 3-kinase and its
downstream targets PKB and BAD, play key roles in prevent-
ing cells from going into apoptosis. However, many aspects of
the mechanisms behind cell survival have remained unclear. In
this report we describe that basal PI 3-kinase is responsible for
maintaining constitutive MAPK activation and that both
wortmannin and LY294002 impair basal but not stimulated
MAPK activity. Although studies performed with pharmaco-
logical agents are often inconclusive, both wortmannin and
LY294002 are known to inhibit PI 3-kinase activity in di¡er-
ent ways. Therefore, we conclude that the e¡ects we observed
are speci¢c. Secondly, we demonstrate the requirement for
both basal PI 3-kinase and basal MAPK activity in quiescent
cells to prevent cell death to occur. Many reports have been
made about wortmannin- and LY294002-sensitive MAPK ac-
tivation by PI 3-kinase [12^14,28]. These studies, however,
concerned the e¡ects of PI 3-kinase inhibitors on insulin- or
PDGF-stimulated MAPK activation, rather than basal activ-
ity of this kinase. We did not observe e¡ects of wortmannin
and LY294002 on MAPK activation after growth factor or
phorbol ester stimulation. Wortmannin-sensitive MAPK acti-
vation by e.g. insulin may be cell type dependent. It is to be
expected that such inhibition is only detected in cell types in
which a weak coupling between growth factor receptors and
the SOS-Ras pathway exists. In our study, we detected a role
for PI 3-kinase in basal MAPK activation in four di¡erent cell
types, therefore, in contrast to a role for PI 3-kinase in in-
duced MAPK activity, its role in basal MAPK activity does
not show much cell type speci¢city. Our report appears to be
in contrast with the observations of e.g. Scheid and Duronio,
Fig. 4. Inhibition of MAPK in quiescent cells, but not in proliferating cells leads to cell death. A: A14 cells were plated and deprived of serum.
After 1 day of serum starvation (t = 0), cells were left untreated or subjected to either PD98059 or LY294002. Cell survival was determined for
4 days, by means of an MTT assay (see Section 2). B: Cells were plated and maintained in the presence of serum (FCS) and treated as de-
scribed above. Lines indicated with dots represent cell survival after incubation with LY294002 for various times. Lines indicated with squares
represent cell survival after incubation with PD98059 for various times. Experiments were performed in 8-fold, S.E.M. are depicted. C: Cells
were incubated with PD98059 for various times and after lysis the samples were used for immunoblotting, using phosphospeci¢c MAPK anti-
bodies.
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1996 [29] who demonstrate wortmannin to have no e¡ect on
MAPK activation in quiescent cells. Therefore it might be
that PI 3-kinase-mediated MAPK activity in quiescent cells
does not occur in all cells, but the data presented in our report
de¢nitely suggest that this may be a very common event. Our
observations seem supported by recent ¢ndings. During our
investigations, Wennstrom and Downward [16] have found a
connection between PI 3-kinase K and MAPK in COS cells
subjected to low dose EGF but not in cells subjected to high
concentrations of EGF. This PI 3-kinase-mediated MAPK
activation was mediated by Shc/Grb2/SOS complexes, and
appears to account for EGF-induced MAPK stimulation at
such concentrations that do not support recruitment of these
complexes to the EGF receptor. From this observation these
authors speculated that basal PI 3-kinase activity might be
responsible for constitutive MAPK activity. Moreover, we
observe that in variety of cell types constitutive MAPK phos-
phorylation is critically dependent on basal PI 3-kinase enzy-
matic activity. We have observed that the PI 3-kinase-induced
constitutive MAPK stimulation is mediated via the Raf/MEK
pathway, and it will be interesting to investigate whether Shc/
Grb2/SOS complexes are involved in our experimental set up
as well.
Interestingly, it has been suggested that integrin signalling is
important in maintaining PI 3-kinase activity in quiescent cells
[30,31], whereas the pivotal function of integrin signalling for
cell survival in quiescent cells is also widely recognised [32,33].
Furthermore, also a function for integrin signalling in constit-
utive MAPK activity has been suggested [34]. In the present
study we have demonstrated that both PI 3-kinase and one of
the components of the MAPK pathway are required for cell
survival of quiescent cells and that PI 3-kinase is the upstream
activator of Raf, MEK and MAPK under these conditions. It
is, therefore, tempting to suggest that integrin-mediated PI 3-
kinase activation and subsequent stimulation of the MAPK
pathway is the major pathway responsible for cell survival in
quiescent cells. Although a role in cell survival has been at-
tributed to MAPK [22], the e¡ect witnessed in this investiga-
tion could also be ascribed to MEK since this MAPK kinase
has also been reported to phosphorylate the anti-apoptotic
protein BAD [5,6].
The nature of the PI 3-kinase isoform, responsible for the
e¡ects demonstrated in this report, remains unknown. Many
authors have suggested the involvement of PI 3-kinase Q, since
PI 3-kinase K constructs were not able to induce MAPK ac-
tivity. However, the expression of PI 3-kinase Q seems limited
to myeloid cells (e.g. [7,35]), suggesting involvement of anoth-
er PI 3-kinase isoform. Wennstrom and Downward suggest a
role for PI 3-kinase K in COS cells making it plausible that
this isoform also regulates MAPK activity in our experimental
set up. Experiments addressing this possibility are currently
performed in our laboratory.
Acknowledgements: This study was supported by a grant from the
Dutch Cancer Society (Koningin Wilhelmina Fonds) and a grant
from the Dutch Heart Foundation (Nederlandse Hart Stichting).
References
[1] Vanhaesebroeck, B., Leevers, S.J., Panayotou, G. and Water¢eld,
M.D. (1997) Trends Biochem. Sci. 22, 267^272.
[2] Arcaro, A. and Wymann, M.P. (1993) Biochem. J. 296, 297^
301.
[3] Vlahos, C.J., Matter, W.F., Hui, K.Y. and Brown, R.F. (1994)
J. Biol. Chem. 269, 5241^5248.
[4] Burgering, B.M. and Co¡er, P.J. (1995) Nature 376, 599^602.
[5] Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y.
and Greenberg, M.E. (1997) Cell 91, 231^241.
[6] del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and
Nunez, G. (1997) Science 278, 687^689.
[7] Stephens, L., Hawkins, P.T., Eguinoa, A. and Cooke, F. (1996)
Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 351, 211^215.
[8] Shaw, L.M., Rabinovitz, I., Wang, H.H., Toker, A. and Mercu-
rio, A.M. (1997) Cell 91, 949^960.
[9] Chen, H.C. and Guan, J.L. (1994) J. Biol. Chem. 269, 31229^
31233.
[10] Rankin, S., Hooshmand-Rad, R., Claesson-Welsh, L. and Ro-
zengurt, E. (1996) J. Biol. Chem. 271, 7829^7834.
[11] Yao, R. and Cooper, G.M. (1995) Science 267, 2003^2006.
[12] Cross, D.A., Alessi, D.R., Vandenheede, J.R., McDowell, H.E.,
Hundal, H.S. and Cohen, P. (1994) Biochem. J. 303, 21^26.
[13] Welsh, G.I., Foulstone, E.J., Young, S.W., Tavare, J.M. and
Proud, C.G. (1994) Biochem. J. 303, 15^20.
[14] Duckworth, B.C. and Cantley, L.C. (1997) J. Biol. Chem. 272,
27665^27670.
[15] Hu, Z.W., Shi, X.Y., Lin, R.Z. and Ho¡man, B.B. (1996) J. Biol.
Chem. 271, 8977^8982.
[16] Wennstrom, S. and Downward, J. (1999) Mol. Cell. Biol. 19,
4279^4288.
[17] Lopez-Ilasaca, M., Crespo, P., Pellici, P.G., Gutkind, J.S. and
Wetzker, R. (1997) Science 275, 394^397.
[18] Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker,
R. and Wymann, M.P. (1998) Science 282, 293^296.
[19] Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaese-
broeck, B., Gout, I., Fry, M.J., Water¢eld, M.D. and Down-
ward, J. (1994) Nature 370, 527^532.
[20] Scheid, M.P. and Duronio, V. (1998) Proc. Natl. Acad. Sci. USA
95, 7439^7444.
[21] Kurada, P. and White, K. (1998) Cell 95, 319^329.
[22] Bergmann, A., Agapite, J., McCall, K. and Steller, H. (1998) Cell
95, 331^341.
[23] Desmedt, M., Rottiers, P., Dooms, H., Fiers, W. and Grooten, J.
(1998) J. Immunol. 160, 5300^5308.
[24] Rubinstein, L.V. et al. (1990) J. Natl. Cancer Inst. 82, 1113^1118.
[25] Payne, D.M. et al. (1991) EMBO J. 10, 885^892.
[26] Marx, J. (1993) Science 262, 988^990.
[27] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel,
A.R. (1995) J. Biol. Chem. 270, 27489^27494.
[28] Conway, A.M., Rakhit, S., Pyne, S. and Pyne, N.J. (1999) Bio-
chem. J. 337, 171^177.
[29] Scheid, M.P. and Duronio, V. (1996) J. Biol. Chem. 271, 18134^
18139.
[30] Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H.
and Downward, J. (1997) EMBO J. 16, 2783^2793.
[31] King, W.G., Mattaliano, M.D., Chan, T.O., Tsichlis, P.N. and
Brugge, J.S. (1997) Mol. Cell. Biol. 17, 4406^4418.
[32] Frisch, S.M. and Francis, H. (1994) J. Cell Biol. 124, 619^626.
[33] Frisch, S.M., Vuori, K., Ruoslahti, E. and Chan-Hui, P.Y. (1996)
J. Cell Biol. 134, 793^799.
[34] Lin, T.H., Aplin, A.E., Shen, Y., Chen, Q., Schaller, M., Romer,
L., Aukhil, I. and Juliano, R.L. (1997) J. Cell Biol. 136, 1385^
1395.
[35] Stoyanov, B. et al. (1995) Science 269, 690^693.
FEBS 23129 27-12-99
H.H. Versteeg et al./FEBS Letters 465 (2000) 69^73 73
